| scholarly article | Q13442814 |
| P2093 | author name string | Anca M Avram | |
| Yuni K Dewaraja | |||
| P2860 | cites work | Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer | Q28262641 |
| 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer | Q30367068 | ||
| Low vs. high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a randomized study | Q33326620 | ||
| Five months' follow-up of patients with and without iodine-positive lymph node metastases of thyroid carcinoma as disclosed by (131)I-SPECT/CT at the first radioablation | Q33516578 | ||
| Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987-2012 | Q33570297 | ||
| Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. | Q33995708 | ||
| Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays. | Q34169009 | ||
| Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer | Q34215677 | ||
| Practical dosimetry of 131I in patients with thyroid carcinoma | Q34577608 | ||
| Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma | Q34578408 | ||
| Radioiodine uptake in thyroid cancer patients after diagnostic application of low-dose 131I | Q71851930 | ||
| Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates | Q73322361 | ||
| 74 MBq radioiodine 131I does not prevent uptake of therapeutic doses of 131I (i.e. it does not cause stunning) in differentiated thyroid cancer | Q73592471 | ||
| Ablation of the thyroid remnant and 131I dose in differentiated thyroid cancer | Q73883538 | ||
| Radioiodine uptake in thyroid remnants during therapy after tracer dosimetry | Q73899824 | ||
| Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I | Q74068084 | ||
| The role of 123I-diagnostic imaging in the follow-up of patients with differentiated thyroid carcinoma as compared to 131I-scanning: avoidance of negative therapeutic uptake due to stunning | Q77067393 | ||
| The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer | Q79346777 | ||
| Outcomes of patients with differentiated thyroid carcinoma following initial therapy | Q79472924 | ||
| [Differentiated thyroid carcinoma--how to improve the long-term results? Twenty-five-year outcomes of 850 patients] | Q80028664 | ||
| The so-called stunning of thyroid tissue | Q80216836 | ||
| A randomized clinical trial comparing 50mCi and 100mCi of iodine-131 for ablation of differentiated thyroid cancers | Q80247426 | ||
| Efficacy of low and high 131I doses for thyroid remnant ablation in patients with differentiated thyroid carcinoma based on post-operative cervical uptake | Q81092096 | ||
| Recurrent/metastatic thyroid carcinomas false negative for serum thyroglobulin but positive by posttherapy I-131 whole body scans | Q81944310 | ||
| 5 mCi pretreatment scanning does not cause stunning when the ablative dose is administered within 72 hours | Q82861200 | ||
| The absorbed dose to the blood is a better predictor of ablation success than the administered 131I activity in thyroid cancer patients | Q83139773 | ||
| The utility of radioiodine scans prior to iodine 131 ablation in patients with well-differentiated thyroid cancer | Q83467030 | ||
| The low utility of pretherapy scans in thyroid cancer patients | Q84327642 | ||
| A randomized equivalence trial to determine the optimum dose of iodine-131 for remnant ablation in differentiated thyroid cancer | Q84515726 | ||
| Treatment and follow-up of low-risk patients with thyroid cancer | Q84723737 | ||
| Staging of Differentiated Thyroid Carcinoma Using Diagnostic 131I SPECT/CT | Q84784137 | ||
| Assessment of lesion response in the initial radioiodine treatment of differentiated thyroid cancer using 124I PET imaging | Q85834659 | ||
| Decreasing the dose of radioiodine for remnant ablation does not increase structural recurrence rates in papillary thyroid carcinoma | Q87022634 | ||
| Radioactive iodine therapy, molecular imaging and serum biomarkers for differentiated thyroid cancer: 2017 guidelines of the French Societies of Nuclear Medicine, Endocrinology, Pathology, Biology, Endocrine Surgery and Head and Neck Surgery | Q88231221 | ||
| Low or Undetectable Basal Thyroglobulin Levels Obviate the Need for Neck Ultrasound in Differentiated Thyroid Cancer Patients After Total Thyroidectomy and 131I Ablation | Q88389232 | ||
| Possible delayed diagnosis and treatment of metastatic differentiated thyroid cancer by adopting the 2015 ATA guidelines | Q89093557 | ||
| Radioiodine treatment after surgery for differentiated thyroid cancer: a reasonable option | Q89305692 | ||
| Bone metastases of differentiated thyroid cancer: impact of early 131I-based detection on outcome | Q34698119 | ||
| Low versus high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a meta-analysis of randomized controlled trials. | Q35201802 | ||
| The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients | Q35790175 | ||
| Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer | Q35855096 | ||
| Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report | Q36302100 | ||
| MIRD pamphlet No. 23: quantitative SPECT for patient-specific 3-dimensional dosimetry in internal radionuclide therapy | Q36302205 | ||
| European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium | Q36489842 | ||
| The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer | Q37650515 | ||
| MIRD pamphlet No. 24: Guidelines for quantitative 131I SPECT in dosimetry applications | Q37675439 | ||
| Thyroid stunning: fact or fiction? | Q37832817 | ||
| Quantitative imaging of (124)I with PET/ CT in pretherapy lesion dosimetry. Effects impairing image quantification and their corrections. | Q37850984 | ||
| Three-dimensional radiobiological dosimetry (3D-RD) with 124I PET for 131I therapy of thyroid cancer | Q37864164 | ||
| Radioiodine scintigraphy with SPECT/CT: an important diagnostic tool for thyroid cancer staging and risk stratification | Q38006934 | ||
| Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer | Q38012414 | ||
| Comparison of Empiric Versus Whole-Body/-Blood Clearance Dosimetry-Based Approach to Radioactive Iodine Treatment in Patients with Metastases from Differentiated Thyroid Cancer | Q39294075 | ||
| 124I PET Assessment of Response of Bone Metastases to Initial Radioiodine Treatment of Differentiated Thyroid Cancer | Q39751199 | ||
| Radioiodine ablation of residual tissue in thyroid cancer: relationship between administered activity, neck uptake and outcome | Q40568695 | ||
| Preablation 131-I scans with SPECT/CT contribute to thyroid cancer risk stratification and 131-I therapy planning | Q41313825 | ||
| Dosimetric considerations in the radioiodine treatment of macrometastases and micrometastases from differentiated thyroid cancer | Q41457157 | ||
| A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer | Q42515151 | ||
| Functioning pulmonary metastases of thyroid cancer: does radioiodine influence the prognosis? | Q43405736 | ||
| Radioiodine-131 therapy for well-differentiated thyroid cancer--a quantitative radiation dosimetric approach: outcome and validation in 85 patients | Q43617702 | ||
| Increasing efficacy and safety of treatments of patients with well-differentiated thyroid carcinoma by measuring body retentions of 131I. | Q44469011 | ||
| The nonimpact of thyroid stunning: remnant ablation rates in 131I-scanned and nonscanned individuals. | Q45991871 | ||
| Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients. | Q46015330 | ||
| Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients | Q46061079 | ||
| Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer | Q47820717 | ||
| Strategies of radioiodine ablation in patients with low-risk thyroid cancer | Q47820730 | ||
| Long-term survival in differentiated thyroid cancer is worse after low-activity initial post-surgical 131I therapy in both high- and low-risk patients. | Q50628764 | ||
| Preablation 131-I scans with SPECT/CT in postoperative thyroid cancer patients: what is the impact on staging? | Q50870247 | ||
| EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy. | Q51956739 | ||
| Dose-Response Relationship in Differentiated Thyroid Cancer Patients Undergoing Radioiodine Treatment Assessed by Means of 124I PET/CT. | Q52984658 | ||
| Incremental value of diagnostic 131I SPECT/CT fusion imaging in the evaluation of differentiated thyroid carcinoma. | Q53385412 | ||
| Comparison of outcomes after (123)I versus (131)I pre-ablation imaging before radioiodine ablation in differentiated thyroid carcinoma. | Q53545950 | ||
| Undetectable or low (<1 ng/ml) postsurgical thyroglobulin values do not rule out metastases in early stage differentiated thyroid cancer patients. | Q55259110 | ||
| Guidelines for radioiodine therapy of differentiated thyroid cancer | Q57482620 | ||
| Prescribing 131Iodine based on neck uptake produces effective thyroid ablation and reduced hospital stay | Q57903308 | ||
| Incidence of radiation thyroiditis and thyroid remnant ablation success rates following 1110 MBq (30 mCi) and 3700 MBq (100 mCi) post-surgical131I ablation therapy for differentiated thyroid carcinoma | Q61654294 | ||
| Comparison of 1073 MBq and 3700 MBq iodine-131 in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid cancer | Q68191091 | ||
| Influence of initial large dose on subsequent uptake of therapeutic radioiodine in thyroid cancer patients | Q69642890 | ||
| An analysis of "ablation of thyroid remnants" with I-131 in 511 patients from 1947-1984: experience at University of Michigan | Q70678022 | ||
| The significance of 1-131 scan dose in patients with thyroid cancer: determination of ablation: concise communication | Q70947555 | ||
| Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer | Q71048700 | ||
| Prospective randomized clinical trial to evaluate the optimal dose of 131 I for remnant ablation in patients with differentiated thyroid carcinoma | Q71102237 | ||
| P433 | issue | 5 | |
| P921 | main subject | thyroid cancer | Q826522 |
| P304 | page(s) | 335-346 | |
| P577 | publication date | 2018-08-04 | |
| P1433 | published in | Clinical and translational imaging | Q26853948 |
| P1476 | title | Thyroid Cancer Radiotheragnostics: the case for activity adjusted 131I therapy | |
| P478 | volume | 6 |
Search more.